SCHEMBL4376937

SCHEMBL4376937

N#Cc1cccc(CON=C2CCN(S(=O)(=O)c3ccc(OCCO)cc3)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 3/20 0.45
MMP1 P03956 2/20 0.45
MMP13 P45452 2/20 0.43
ADAMTS4 O75173 1/20 0.43
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MMP3 P08254 1/20 0.40
MMP7 P09237 1/20 0.40
FFAR1 O14842 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ATM Q13315 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.38
MET P08581 1/20 0.37
CYP2C9 P11712 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386136 0.93 ADAM17 (0.43) ADAM17MMP1MMP13ADAMTS4MAOA
SCHEMBL4391254 0.92 ADAM17 (0.44) ADAM17MMP1MMP13ADAMTS4MAOA
SCHEMBL4382627 0.90 ADAM17 (0.42) ADAM17MMP1MMP13ADAMTS4MAOA
SCHEMBL13589015 0.89 CYP3A4 (0.43) ADAM17MMP1L3MBTL1ATMMAPK1
SCHEMBL4380262 0.88 LMNA (0.48) ADAM17MMP1L3MBTL1TSHRMAPK1
SCHEMBL8225081 0.86 RORC (0.43) ADAM17MMP1L3MBTL1ATM
SCHEMBL4380777 0.86 ADAM17 (0.40) ADAM17MMP1MMP13ADAMTS4CYP2C9
SCHEMBL4384704 0.85 L3MBTL1 (0.45) ADAM17MMP1MAOAMAOBL3MBTL1
SCHEMBL4388230 0.85 MEN1 (0.46) ADAM17MMP1MMP13ADAMTS4MAOA
SCHEMBL4385773 0.85 ADAM17 (0.43) ADAM17MMP1MMP13ADAMTS4MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 ADAM17 4249/4885MMP1 4626/4885MMP13 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.